本資料は、掲載誌(URI)等のリンク先にある学位授与機関のWebサイトやCiNii Dissertationsから、本文を自由に閲覧できる場合があります。
博士論文
国立国会図書館館内限定公開
収録元データベースで確認する
国立国会図書館デジタルコレクション
デジタルデータあり
公開元のウェブサイトで確認する
DOI[info:doi/10.1253/circj.CJ-15-0617]のデータに遷移します
Beta-Blockers and Fetal Growth Restriction in Pregnant Women With Cardiovascular Disease
- 国立国会図書館永続的識別子
- info:ndljp/pid/11378278
国立国会図書館での利用に関する注記
資料に関する注記
一般注記:
- application/pdfPregnant women with cardiovascular disease may need drug treatment, depending on the disease severity and type. Drug treatment during p...
書店で探す
障害者向け資料で読む
目次
2023-12-15 再収集
書店で探す
障害者向け資料で読む
書誌情報
この資料の詳細や典拠(同じ主題の資料を指すキーワード、著者名)等を確認できます。
デジタル
- 資料種別
- 博士論文
- 著者・編者
- Tanaka, Kayo
- 著者標目
- 出版事項
- 出版年月日等
- 2019-03-25
- 出版年(W3CDTF)
- 2019-03-25
- 授与機関名
- 三重大学
- 授与年月日
- 2019-03-25
- 授与年月日(W3CDTF)
- 2019-03-25
- 報告番号
- 甲医学第1933号
- 学位
- 博士(医学)
- 博論授与番号
- 甲医学第1933号
- 本文の言語コード
- eng
- 対象利用者
- 一般
- 一般注記
- application/pdfPregnant women with cardiovascular disease may need drug treatment, depending on the disease severity and type. Drug treatment during pregnancy should be individualized based on the maternal-fetal risk and benefit. Pregnancy increases the circulating blood volume and cardiac output by increasing the ventricular rate and stroke volume and decreasing peripheral vascular resistance. Circulating blood volume increases more rapidly after 20 gestational weeks, and the blood volume at 28–32 gestational weeks is 40–45% greater than the nonpregnancy volume. Therefore, in some pregnancies in women with cardiovascular disease, drug treatment needs to be initiated during pregnancy. For many years, β-adrenergic blockers have been used to treat hypertension in pregnant women. In addition, α/β-adrenergic blockers and β-adrenergic blockers are very often used to control arrhythmias and ventricular dysfunction in pregnant women with cardiovascular disease. It has been suggested, however, that β-adrenergic blockers are associated with fetal growth restriction (FGR). The US Food and Drug Administration (FDA) classifies β-adrenergic blockers as pregnancy category C drugs during the first and second trimesters and as pregnancy category D drugs during the third trimester. The FDA has classified the fetal risk of gestational prescription drug use into 5 categories: A, B, C, D, and X. Category C drugs carry risks that cannot be ruled out, but well-controlled clinical or animal studies showing a fetal risk have not been reported. Fetal damage is likely if these drugs are used during pregnancy, but their potential benefits may exceed their potential risks. Category D drugs carry evidence of risk. For these drugs, human studies conducted during pre- or post-marketing investigations demonstrated a fetal risk, but the potential benefits of these drugs may outweigh their potential risk. In a 1990 study, Butters et al examined pregnant women with hypertension. They compared patients treated with a β-adrenergic blocker, atenolol, with patients who did not receive medication and found a significantly higher rate of FGR in the atenolol group compared with the no-medication group. The fetal effects of α/β- and β-adrenergic blockers clearly merit further research. The aim of the present study was therefore to analyze the maternal and neonatal outcomes of pregnancy in women with cardiovascular disease who were treated with an α/β- or β-adrenergic blocker. The broader goal was to clarify the effects of these drugs in order to improve the drug treatment options for pregnant women with cardiovascular disease.本文/Department of Obstetrics and Gynecology, Faculty of Medicine, Mie University, Tsu, Japan6p
- DOI
- info:doi/10.1253/circj.CJ-15-0617
- 国立国会図書館永続的識別子
- info:ndljp/pid/11378278
- コレクション(共通)
- コレクション(障害者向け資料:レベル1)
- コレクション(個別)
- 国立国会図書館デジタルコレクション > デジタル化資料 > 博士論文
- 収集根拠
- 博士論文(自動収集)
- 受理日(W3CDTF)
- 2019-11-04T14:30:53+09:00
- 作成日(W3CDTF)
- 2019-10-15
- 記録形式(IMT)
- application/pdf
- オンライン閲覧公開範囲
- 国立国会図書館内限定公開
- デジタル化資料送信
- 図書館・個人送信対象外
- 遠隔複写可否(NDL)
- 可
- 連携機関・データベース
- 国立国会図書館 : 国立国会図書館デジタルコレクション